Delayed musculoskeletal symptoms after breast radiotherapy can reflect osteoradionecrosis rather than recurrence, thus ...

Preoperative axillary ultrasound and MRI effectively predict sentinel lymph node status, guiding safe SLNB de-escalation in ...

Dana Friesen, CEO of Summit Sciences, brings over 15 years of experience in financial analysis and ROI optimization within the medical device sector. The firm has delivered billions in lifetime ...

In the AXSANA/EUBREAST 3(R) study, researchers compared data about recurrence outcomes of more-invasive and less-invasive lymph node procedures.

Of all the types of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and lacks specific therapies.

Enhertu received FDA breakthrough therapy designation for HER2-positive early breast cancer with residual invasive disease post-neoadjuvant treatment. DESTINY-Breast05 trial showed Enhertu's ...

Of all the types of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and lacks specific therapies.

A new study published in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center details a therapeutic vulnerability in patients with an aggressive subtype ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.